6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026

COMMISSION FILE NUMBER 001-34041

Evotec SE(Translation of registrant’s name into English)

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On January 8, 2026, Evotec SE (the “Company”) issued a press release announcing the receipt of a new grant from the Gates Foundation, attached hereto as Exhibit 99.1, and submitted a Notification of Major Holdings to Bundesanstalt für Finanzdienstleistungsaufsicht, pursuant to German Law, attached hereto as Exhibit 99.2.

EXHIBIT INDEX

SIGNATURE

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 8, 2026

Exhibit 99.1

Just – Evotec Biologics ReceivesGrant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Hamburg, Germany, January 08,2026:

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announces that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just – Evotec Biologics’ molecular design suite of computational technologies, called “J.MD™”.

Investment (INV072135) continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to make them more affordable and accessible and prevent infectious disease in low- and middle-income countries.

Under the grant terms, Just – Evotec Biologics will leverage its J.MD™ Molecular Design service - a key component of its J.DESIGN™ platform, that integrates advanced computational tools and high-throughput methodologies to streamline the biologics development process. By optimizing molecular design from the earliest stages, J.MD™ ensures manufacturability, stability, and efficacy—critical factors for reducing costs and enabling expansion of global access to these therapies as well as limiting liabilities like immunogenicity and instability. The new investment will enable ten (10) new J.MD™ projects over the next three years, spanning the development of biotherapeutics targeting multiple global health disease indications of concern.

This grant extends the commitment of Just – Evotec Biologics, that began in 2014 and has since delivered multiple cGMP manufacturing campaigns for RSV, Malaria, and HIV monoclonal antibodies.

Dr. LindaZuckerman, EVP and Global Head of Just – Evotec Biologics, commented: “We are thrilled to receive this new grant from the Gates Foundation which will strengthen our commitment to reducing the cost of biologics development to expand global access. By leveraging our J.DESIGN™ platform and innovative molecular design tools, we look forward to supporting the foundation in driving impactful solutions across multiple disease areas and continuing to deliver therapies where they are needed most.”

Page 1 of 3

Dr. Cord Dohrmann, Chief ScientificOfficer of Evotec, added: “We are proud to continue our collaboration with the foundation through this new grant which enables us to harness Just – Evotec Biologics’ advanced platforms and scientific expertise to support the broader research ecosystem. This partnership strengthens our shared mission to accelerate the development of biotherapeutics that address urgent and unmet medical needs.”

For expert insights about the importance of thoughtful antibody design driving global access, watch our virtual roundtable, Antibody Design to Support Global Health Initiatives, featuring key voices from the Gates Foundation and global health researchers.

About Just – Evotec Biologics

Just – Evotec Biologics, whollyowned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design,cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery throughclinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data,protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through thescientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand accessto biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learnmore at www.just-evotecbiologics.com.

About Evotec SE

Evotec is a life science companythat is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advancedtechnologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules,biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmicsand iPSC-based disease modeling.

With flexible partnering models tailoredto our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders.Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientificexcellence with operational agility.

Through Just – Evotec Biologics,we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolicdiseases, neurology, and immunology.

Evotec’s global team of morethan 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centersof excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-lookingstatements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such wordsand similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’sexpectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the informationavailable to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance canbe given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upona number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which arebeyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisionsto any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any changein events, conditions or circumstances on which any statement is based.

Page 2 of 3

For further information, please contact:

Investor Relations and Media Contact

Dr. Sarah Fakih

EVP Head of Global Communications &Investor Relations

[email protected]

Page 3 of 3

Exhibit 99.2